The lowest advertised price is usually a starter-dose or prepaid figure. Total monthly cost is driven by your dose, your plan length, and what’s bundled. This page compares providers at a starter dose and a maintenance dose so you can see the ranking flip.
There is no single cheapest provider. At a starter dose, a dose-tiered provider (Fifty 410) advertises the lowest entry price. At a maintenance dose, dose-tiered prices climb, so flat-rate providers (Henry Meds, NexLife) can become the lower total. Price your actual maintenance dose.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Model | Starter (~2.5mg) | Maintenance (~10–15mg) | Membership | Provenance |
|---|---|---|---|---|---|
| Fifty 410 | Dose-tiered | from ~$133 | rises (~$166–$299+) | None | primary+sec |
| Henry Meds | Flat | $179 | $179 | None (stated) | secondary |
| NexLife | Flat | $215 / ~$186 (12mo) | same | None (stated) | primary |
| Mochi Health | Membership + add-on | ~$278 | ~$278+ | ~$79 req. | secondary |
Independent 2026 cost guides put typical compounded tirzepatide at roughly $300–$600/month depending on dose and program, so verify the price at your maintenance dose before assuming the entry number holds.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.